Takahashi I, Uchida K, Ohmoto E, Endo H, Oda Y, Fujimoto S, Hara M, Takaoka K, Watanabe S, Lai M, Kohi F, Kitajima K, Kimura I, Sanada H, Tokioka M, Adachi T, Yorimitsu S
Gan To Kagaku Ryoho. 1982 Jul;9(6):1091-6.
Eighteen patients with acute lymphocytic leukemia (ALL) were treated with VP (vincristine, prednisolone) followed by DVMP (daunorubicin + vincristine + 6-mercaptopurine + prednisolone) regimen (VP-DVMP regimen). Patients were all previously untreated. Complete remission (CR) was obtained in 11 of 18 patients (61.1%,) by VP alone and 4 patients, by VP-DVMP. The time required for CR varied from 14 to 60 days with a median of 28 days. The duration of CR and survivals in responders were from 1.2 to 42.3 + months with a median of 24.0 months. The hematological toxicities in VP-DVMP regimen were lower than those in NVP (neocarzinostatin + vincristine + prednisolone) and NVMP (neocarzinostatin + vincristine + 6-mercaptopurine + prednisolone) regimens.
